GI
DYN icon

GAMMA Investing’s Dyne Therapeutics DYN Stock Holding History

GAMMA Investing’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$30.3K Buy
1,882
+729
+63% +$16.7K ﹤0.01% 2686
2026
Q2 		$25.6K Buy
1,153
+104
+10% +$1.93K ﹤0.01% 2704
2026
Q1 		$19K Buy
1,049
+208
+25% +$3.59K ﹤0.01% 2739
2025
Q4 		$16.4K Buy
841
+192
+30% +$3.64K ﹤0.01% 2716
2025
Q3 		$8.21K Buy
649
+137
+27% +$1.56K ﹤0.01% 2975
2025
Q2 		$4.87K Buy
512
+261
+104% +$2.87K ﹤0.01% 3131
2025
Q1 		$2.63K Sell
251
-29
-10% -$415 ﹤0.01% 3328
2024
Q4 		$6.6K Buy
280
+43
+18% +$1.27K ﹤0.01% 2794
2024
Q3 		$8.51K Buy
237
+41
+21% +$1.63K ﹤0.01% 2525
2024
Q2 		$6.92K Buy
196
+18
+10% +$523 ﹤0.01% 2424
2024
Q1 		$5.05K Buy
178
+16
+10% +$362 ﹤0.01% 2406
2023
Q4 		$3.47K Buy
+162
New +$1.58K ﹤0.01% 2388

Other funds holding DYN

VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's DYN Position: Q3 2026 in Review

GAMMA Investing increased its Dyne Therapeutics (DYN) stake by 63% in Q3 2026, buying an estimated $16.7K and bringing the position to 1,882 shares worth $30.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2686.

GAMMA Investing first reported a position in DYN in Q4 2023 and has held it in 12 quarters since. 4 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • GAMMA Investing held 1,882 shares of Dyne Therapeutics worth $30.3K as of Q3 2026.
  • GAMMA Investing bought 729 Dyne Therapeutics shares in Q3 2026, an estimated $16.7K.
  • Dyne Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2686 holding.
  • GAMMA Investing first reported a position in Dyne Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • 4 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.